Clinical Trials - The Importance of Diversity in Clinical Trials

Clinical Trials - The Importance of Diversity in Clinical Trials

Summary

This report provides an analysis of clinical trial racial representation data and evaluates racial demographics across a number of clinical trials sectors to highlight the level of diversity.

Analysis of Racial Representation across Multiple Clinical Trial Sectors

ScopeThe clinical trials data used for these analyses was extracted from GlobalData’s Clinical Trials Database, captured on June 16 and July 19, 2022. The data primarily includes clinical trials initiated from January 1, 2013 to June 16, 2022. Disclosed racial representation data has been analyzed by location, by year, phase, therapy area, sponsor type, top industry sponsors, pivotal study status, single country and multinational trials, decentralized trials, and CRO involvement. Additional analysis on obstacles in the recruitment of diverse subject populations in clinical trials and steps which can be taken to increase diversity have also been included.Reasons to BuyProvides a breakdown of racial representation data across a number of clinical trial sectors. Identifies which areas are lacking in clinical trial population diversity. Highlights the variation in diversity in the industry and against institutional sponsors. Documents the barriers to diversity in clinical trials and outlines steps to improve it.Assesses how decentralized and virtual components in clinical trials affect diversity.